NEW YORK, Feb. 07, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Natus Medical Incorporated (“Natus” or the “Company”) (NASDAQ:BABY) and certain of its officers, and is on behalf of shareholders who purchased or otherwise acquired Natus Medical Incorporated securities between October 16, 2015 and April 3, 2016, both dates inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/baby.
The class action lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose material adverse facts about Natus’ business, operations, and prospects, including that: (1) the Venezuelan government failed to make tens of millions of dollars in prepayments to Natus, which were required to have been paid beginning in October 2015; (2) Natus had no means to effectively enforce its rights under its supply contract, as Venezuela was the exclusive forum for dispute resolution; (3) Natus’ receipt of revenues pursuant to the supply contract was contingent on the outcome of Venezuelan elections; and (4) consequently, Natus was not on track to achieve the increased guidance provided by Defendants, which lacked a reasonable basis. Once this information was made known to the investing public, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/baby or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Natus you have until March 31, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Italy Fines Apple €98.6 Million Over App Store Dominance
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
Warner Bros Discovery Weighs Amended Paramount Skydance Bid as Netflix Takeover Battle Intensifies
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions
Mexico Antitrust Review of Viva Aerobus–Volaris Deal Signals Growth for Airline Sector
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 



